These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
267 related items for PubMed ID: 8717399
1. Development of novel vaccines against anthrax in man. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. J Biotechnol; 1996 Jan 26; 44(1-3):155-60. PubMed ID: 8717399 [Abstract] [Full Text] [Related]
2. [Progress on the vaccine for anthrax]. Zhan DW, Wang P, Wang LC, Zhang ZS. Wei Sheng Wu Xue Bao; 2005 Feb 26; 45(1):149-52. PubMed ID: 15847185 [Abstract] [Full Text] [Related]
3. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C. Vaccine; 2006 May 01; 24(18):3953-63. PubMed ID: 16530302 [Abstract] [Full Text] [Related]
8. [Mixed vaccine against bacterial anthrax and symptomatic anthrax]. Blancou JM. Rev Elev Med Vet Pays Trop; 1974 Sep 01; 27(2):183-7. PubMed ID: 4219888 [No Abstract] [Full Text] [Related]
9. Anthrax capsule vaccine protects against experimental infection. Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM. Vaccine; 2004 Nov 15; 23(1):43-7. PubMed ID: 15519706 [Abstract] [Full Text] [Related]
10. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. Doolan DL, Freilich DA, Brice GT, Burgess TH, Berzins MP, Bull RL, Graber NL, Dabbs JL, Shatney LL, Blazes DL, Bebris LM, Malone MF, Eisold JF, Mateczun AJ, Martin GJ. J Infect Dis; 2007 Jan 15; 195(2):174-84. PubMed ID: 17191162 [Abstract] [Full Text] [Related]
11. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Sloat BR, Cui Z. Vaccine; 2006 Sep 29; 24(40-41):6405-13. PubMed ID: 16828937 [Abstract] [Full Text] [Related]
12. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Mendelson I, Gat O, Aloni-Grinstein R, Altboum Z, Inbar I, Kronman C, Bar-Haim E, Cohen S, Velan B, Shafferman A. Vaccine; 2005 Dec 01; 23(48-49):5688-97. PubMed ID: 16039760 [Abstract] [Full Text] [Related]
13. Anthrax vaccine. Med Lett Drugs Ther; 1998 May 08; 40(1026):52-3. PubMed ID: 9599595 [No Abstract] [Full Text] [Related]
17. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Herrmann JE, Wang S, Zhang C, Panchal RG, Bavari S, Lyons CR, Lovchik JA, Golding B, Shiloach J, Lu S. Vaccine; 2006 Jul 26; 24(31-32):5872-80. PubMed ID: 16790303 [Abstract] [Full Text] [Related]
18. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Flick-Smith HC, Waters EL, Walker NJ, Miller J, Stagg AJ, Green M, Williamson ED. Microb Pathog; 2005 Jan 26; 38(1):33-40. PubMed ID: 15652293 [Abstract] [Full Text] [Related]
19. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. Sloat BR, Cui Z. J Pharm Pharmacol; 2006 Apr 26; 58(4):439-47. PubMed ID: 16597361 [Abstract] [Full Text] [Related]
20. Molecular basis for improved anthrax vaccines. Brey RN. Adv Drug Deliv Rev; 2005 Jun 17; 57(9):1266-92. PubMed ID: 15935874 [Abstract] [Full Text] [Related] Page: [Next] [New Search]